KalVista Pharmaceuticals, Inc. (KALV)

Market Cap	771.81M
Revenue (ttm)	n/a
Net Income (ttm)	-183.44M
Shares Out	49.76M
EPS (ttm)	-3.69
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,008,595
Open	16.00
Previous Close	15.99
Day's Range	15.08 - 16.32
52-Week Range	7.30 - 16.32
Beta	-0.04
Analysts	Strong Buy
Price Target	26.29 (+69.5%)
Earnings Date	Jul 10, 2025

About KALV

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID f...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Benjamin Palleiko
• Employees: 150
• Stock Exchange: NASDAQ
• Ticker Symbol: KALV
• Website: https://www.kalvista.com

Analyst Summary

According to 9 analysts, the average rating for KALV stock is "Strong Buy." The 12-month stock price target is $26.29, which is an increase of 69.50% from the latest price.

Price Target

$26.29

(69.50% upside)

Analyst Consensus: Strong Buy